Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

, ESRX

Express Scripts

$70.57

0.51 (0.73%)

08:57
10/11/16
10/11
08:57
10/11/16
08:57

Horizon Pharma sees FY16 adjusted net sales at low end of $1.02B-$1.05B

Consensus $1.03B. Horizon Pharma (HZNP) is providing estimates of certain Q3 results, confirming expected net sales on a non-GAAP adjusted basis at the low end of its previously announced full-year net sales guidance range and revising its full-year 2016 adjusted EBITDA guidance range, reflecting higher fourth-quarter investment spending. The additional operating expenses reflect strategic investments the company is making to support future growth opportunities, particularly as it transitions its business mix toward orphan disease medicines and builds a more durable primary care business, Horizon stated in a regulatory filing. The company anticipates, on a GAAP basis including the previously announced $65M settlement with Express Scripts (ESRX) as a one-time reduction in GAAP net sales, its full-year 2016 net sales will be approximately $960M. Excluding the $65M settlement, the company now expects that net sales on a non-GAAP adjusted basis will be at the low end of its previously announced full-year net sales guidance range of $1.025B-$1.05B, or approximately $1.025B. The exclusion of the $65M settlement from GAAP net sales guidance is the only adjustment reflected in Horizon Pharma's full-year 2016 non-GAAP adjusted net sales guidance. The company is revising its full-year 2016 adjusted EBITDA guidance range as the result of expected net sales at the low end of its non-GAAP adjusted net sales guidance range and anticipated higher investment spending in the fourth quarter of 2016 and now expects adjusted EBITDA to be in the range of $450M-$460M, prior range was $495M-$510M. The company's full-year 2016 guidance does not include the previously announced expected acquisition of Raptor Pharmaceutical Corp.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

ESRX

Express Scripts

$70.57

0.51 (0.73%)

  • 26

    Oct

  • 06

    Nov

  • 14

    Dec

HZNP Horizon Pharma
$19.52

0.79 (4.22%)

08/02/16
BMOC
08/02/16
NO CHANGE
BMOC
Outperform
Horizon Pharma scored 'important win' with CVS, says BMO Capital
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
09/13/16
BMUR
09/13/16
NO CHANGE
Target $32
BMUR
Buy
Horizon Pharma acquisition a positive, says Brean Capital
Brean Capital analyst Difei Yang said she is positive on Horizon Pharma's (HZNP) deal for Raptor Pharmaceuticals (RPTP). The analyst cited Horizon executing on its transformative strategy into an orphan disease company, the reasonable price paid for the company, and the moderate growth opportunities for synergies between the two. Yang reiterated her Buy rating and raised her price target to $32 from $30 on Horizon Pharma shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Horizon Pharma patent loss immaterial, says JMP Securities
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Horizon Pharma added to US Small Cap Fundamental List at BMO Capital
ESRX Express Scripts
$70.57

0.51 (0.73%)

08/09/16
LEER
08/09/16
NO CHANGE
Target $110
LEER
Outperform
Leerink remains positive on CVS Health long-term fundamentals
Leerink analyst David Larsen continues to be positive on CVS' (CVS) long-term fundamentals. The analyst notes that the company is having a successful 2017 selling season, with a retention rate higher than what it was last year, and says its Q3 should benefit from a number of break-even generics. Further, Larsen says the company is being more aggressive than Express Scripts (ESRX) with regards to formulary management, and believes that if CVS provides a 5-year outlook in December, shares will likely rally. Larsen reiterates an Outperform rating and $110 rating on CVS' shares.
08/15/16
LEER
08/15/16
NO CHANGE
LEER
Outperform
Leerink more positive on CVS after Formulary exclusions lists
Leerink analyst David Larsen says he's incrementally more positive on CVS Health (CVS) after the company and Express Scripts (ESRX) published their 2017 National Preferred Formulary exclusions lists. CVS is being more aggressive about using bio-similar products and has excluded about 10 products due to hyperinflation trends, Larsen tells investors in a research note. Express Scripts is excluding around 85 products in 2017, which is almost half of the 153 products being excluded by CVS, the analyst writes. He keeps an Outperform rating on CVS and a Market Perform ration on Express Scripts.
08/29/16
LEER
08/29/16
NO CHANGE
LEER
EpiPen price is Mylan's issue, says Leerink
Leerink analyst David Larsen says the recent weakness in pharmacy benefit managers and the drug distribution group is "overdone," as he believes Mylan (MYL) has been taking the vast majority of the pricing increases that have occurred with EpiPen, not the pharmacy benefit managers and distributors. Further, the analyst estimates that Cardinal Health (CAH) has a "fee-for-service" deal with EpiPen, which means that there may be no benefit to the company for any price increase that occurs, and notes that Express Scripts (ESRX) gives back 80%-90% of EpiPen rebates to their plan customers. Larsen would be a buyer of CVS Health (CVS) on weakness.
10/05/16
UBSW
10/05/16
INITIATION
Target $76
UBSW
Neutral
Express Scripts initiated with a Neutral at UBS
Target $76.

TODAY'S FREE FLY STORIES

PKE

Park Electrochemical

$18.66

0.02 (0.11%)

06:31
06/28/17
06/28
06:31
06/28/17
06:31
Earnings
Park Electrochemical reports Q1 EPS before items 12c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$20.02

5.62 (39.03%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Recommendations
CB&I analyst commentary  »

Court ruling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

, TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Periodicals
Toshiba to file $1B lawsuit against Western Digital, Reuters reports »

Toshiba (TOSBF, TOSYY)…

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

WDC

Western Digital

$91.85

-0.81 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOP

Koppers Holdings

$34.00

-0.7 (-2.02%)

06:22
06/28/17
06/28
06:22
06/28/17
06:22
Upgrade
Koppers Holdings rating change  »

Koppers Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRB

H&R Block

$31.34

0.02 (0.06%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
H&R Block management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

, SYMC

Symantec

$28.11

-0.75 (-2.60%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Recommendations
Proofpoint, Symantec analyst commentary  »

Piper highlights…

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

SYMC

Symantec

$28.11

-0.75 (-2.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$34.48

0.1 (0.29%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
Houlihan Lokey management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HAL

Halliburton

$41.53

-0.17 (-0.41%)

06:17
06/28/17
06/28
06:17
06/28/17
06:17
Conference/Events
Halliburton management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 24

    Jul

FIVE

Five Below

$47.79

-0.545 (-1.13%)

06:16
06/28/17
06/28
06:16
06/28/17
06:16
Conference/Events
Five Below management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

AABA

Altaba

$53.64

-0.67 (-1.23%)

, BABA

Alibaba

$141.53

-1.2 (-0.84%)

06:15
06/28/17
06/28
06:15
06/28/17
06:15
Initiation
Altaba, Alibaba, Yahoo Japan initiated  »

Altaba initiated with an…

AABA

Altaba

$53.64

-0.67 (-1.23%)

BABA

Alibaba

$141.53

-1.2 (-0.84%)

YAHOY

Yahoo Japan

$8.77

0.05 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GIL

Gildan Activewear

$31.44

-0.3 (-0.95%)

06:08
06/28/17
06/28
06:08
06/28/17
06:08
Upgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:07
06/28/17
06/28
06:07
06/28/17
06:07
Syndicate
Government Properties files to sell 25M shares of common stock »

The joint bookrunning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRNT

Ceragon Networks

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Hot Stocks
Ceragon Networks receives new orders from Tier 1 South Cone operator »

Ceragon Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

FDC

First Data

$18.53

-0.18 (-0.96%)

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Downgrade
First Data rating change  »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGOV

NIC Inc.

$19.00

-0.55 (-2.81%)

06:05
06/28/17
06/28
06:05
06/28/17
06:05
Initiation
NIC Inc. initiated  »

NIC Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:02
06/28/17
06/28
06:02
06/28/17
06:02
Hot Stocks
First Potomac to be acquired by Government Properties in $1.4B deal »

First Potomac Realty…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:01
06/28/17
06/28
06:01
06/28/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Hot Stocks
Breaking Hot Stocks news story on First Potomac, Government Properties »

First Potomac to be…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$21.13

-0.18 (-0.84%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Syndicate
Canada Goose 12.5M share Secondary priced at $20.75 »

CIBC, Credit Suisse,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RGEN

Repligen

$43.25

-2.09 (-4.61%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Syndicate
Repligen 2.807M share Spot Secondary priced at $42.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GDX

Market Vector Gold Miners

$22.26

-0.3 (-1.33%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.81

0.45 (0.38%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.50

-1.23 (-3.76%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYG

Tortoise Energy

$29.13

-0.14 (-0.48%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Upgrade
Tortoise Energy rating change  »

Tortoise Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.89

-0.46 (-2.38%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.